VYNE Therapeutics (VYNE) Interest Expenses (2016 - 2025)
VYNE Therapeutics (VYNE) posted Interest Expenses of $2000.0 for Q2 2025, down 98.41% on a QoQ basis from $126000.0 in Q4 2024, and down 96.55% year-over-year from $58000.0 in Q2 2024.
VYNE Therapeutics (VYNE) Interest Expenses (2016 - 2025) Analysis & Trends
VYNE Therapeutics' Interest Expenses history runs 9 years deep, the most recent figure standing at $2000.0 for Q2 2025.
- Quarterly Interest Expenses fell 96.55% year-over-year to $2000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $2000.0 (down 96.55% YoY) and the FY2025 annual result came in at $112000.0, down 99.89% from the prior year.
- Interest Expenses was $2000.0 for Q2 2025 at VYNE Therapeutics, down from $126000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $3.5 million in Q3 2021 and bottomed at -$3.2 million in Q4 2021.
- A 4-year average of $268769.2 and a median of $126000.0 in 2024 frame the typical range for Interest Expenses.
- Peak annual rise in Interest Expenses reached 357.14% in 2024, while the deepest fall reached 99.33% in 2024.
- VYNE Therapeutics' Interest Expenses stood at -$3.2 million in 2021, then jumped by 98.48% to -$49000.0 in 2023, then surged by 357.14% to $126000.0 in 2024, then slumped by 98.41% to $2000.0 in 2025.
- Business Quant data shows VYNE's Interest Expenses at $2000.0 in Q2 2025, $126000.0 in Q4 2024, and $2000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -42,141.15 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 100,000.00 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 32.89 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 420.30 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 28.30 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 1.17 Bn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 2,000.00 |
| Dec 31, 2024 | 126,000.00 |
| Dec 31, 2024 | 126,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Sep 30, 2024 | 2,000.00 |
| Jun 30, 2024 | 58,000.00 |
| Jun 30, 2024 | 58,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | -49,000.00 |
| Dec 31, 2023 | -49,000.00 |
| Sep 30, 2023 | 300,000.00 |
| Sep 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Mar 31, 2023 | 300,000.00 |
| Mar 31, 2023 | 300,000.00 |
| Dec 31, 2021 | -3.23 Mn |
| Dec 31, 2021 | -3.23 Mn |